Zevra Therapeutics (ZVRA)
Commercializes U.S.-approved therapies for Niemann-Pick type C disease and certain urea-cycle disorders.
$11.27
vs last close−0.31 (−2.68%)
Something off on this page? Send us feedback.
Next report
Nov 4, 26
in 42 days
EPS estimate
$0.14
Revenue estimate
$37.1M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.67−$0.06$1.21−$0.01$0.21$0.60$0.14Pending
Estimate−$0.39−$0.21$2.19−$0.02$0.05$0.06$0.11$0.14
Surprise−71.8%+71.4%−44.7%+50.0%+316.7%+900.0%+27.3%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$12.0M$20.4M$25.9M$26.1M$34.1M$36.2M$39.7MPending
Estimate$16.7M$21.1M$24.5M$26.6M$28.1M$32.0M$33.9M$37.1M
Surprise−27.7%−3.2%+5.6%−2.2%+21.6%+13.3%+17.1%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $0.40 | — | — |
| Sep 2028 | $0.37 | — | — |
| Jun 2028 | $0.34 | — | — |
| Mar 2028 | $0.28 | — | — |
| Dec 2027 | $0.31 | — | — |
| Sep 2027 | $0.29 | — | — |
| Jun 2027 | $0.27 | — | — |
| Mar 2027 | $0.24 | — | — |
| Dec 2026 | $0.18 | — | — |
| Nov 2026 | $0.14 | — | — |
| Aug 2026 | $0.11 | $0.14 | +27.3% |
| May 2026 | $0.06 | $0.60 | +900.0% |
| Mar 2026 | $0.05 | $0.21 | +316.7% |
| Nov 2025 | −$0.02 | −$0.01 | +50.0% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Oct 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $0.40 | — | — | $62.0M | — | — | — |
| Sep 2028 | $0.37 | — | — | $58.7M | — | — | — |
| Jun 2028 | $0.34 | — | — | $55.5M | — | — | — |
| Mar 2028 | $0.28 | — | — | $49.9M | — | — | — |
| Dec 2027 | $0.31 | — | — | $48.7M | — | — | — |
| Sep 2027 | $0.29 | — | — | $46.7M | — | — | — |
| Jun 2027 | $0.27 | — | — | $44.4M | — | — | — |
| Mar 2027 | $0.24 | — | — | $41.3M | — | — | — |
| Dec 2026 | $0.18 | — | — | $39.6M | — | — | — |
| Nov 4, 2026 | $0.14 | — | — | $37.1M | — | — | — |
| Aug 5, 2026 | $0.11 | $0.14 | +27.3% | $33.9M | $39.7M | +17.1% | +12.8% |
| May 6, 2026 | $0.06 | $0.60 | +900.0% | $32.0M | $36.2M | +13.3% | −2.2% |
| Mar 9, 2026 | $0.05 | $0.21 | +316.7% | $28.1M | $34.1M | +21.6% | +21.3% |
| Nov 5, 2025 | −$0.02 | −$0.01 | +50.0% | $26.6M | $26.1M | −2.2% | −9.7% |
| Aug 12, 2025 | |||||||
| May 13, 2025 | |||||||
| Mar 11, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 13, 2024 | |||||||
| May 8, 2024 | |||||||
| Mar 28, 2024 | |||||||
| Nov 7, 2023 | |||||||
| Aug 14, 2023 | |||||||
| May 15, 2023 | |||||||
| Mar 7, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 11, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 30, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 12, 2021 | |||||||
| May 13, 2021 | |||||||
| Mar 11, 2021 | |||||||
| Oct 29, 2020 | |||||||
| Aug 12, 2020 | |||||||
| May 12, 2020 | |||||||
| Feb 28, 2020 | |||||||
| Nov 14, 2019 | |||||||
| Aug 13, 2019 | |||||||
| May 14, 2019 | |||||||
| Feb 28, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 9, 2018 | |||||||
| May 10, 2018 | |||||||
| Mar 29, 2018 | |||||||
| Nov 9, 2017 | |||||||
| Aug 10, 2017 | |||||||
| May 10, 2017 | |||||||
| Mar 9, 2017 | |||||||
| Nov 9, 2016 | |||||||
| Aug 10, 2016 | |||||||
| May 12, 2016 | |||||||
| Mar 10, 2016 | |||||||
| Nov 12, 2015 | |||||||
| Aug 13, 2015 |